Monitor for full preclinical data presentation in late 2026, which could serve as a catalyst if results are compelling. Near-term stock movement likely muted given early stage.
Price Chart
Executive Summary
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates greater anti-tumor activity in solid tumor models. The company plans additional studies in pancreatic and colorectal cancer, with full data expected in late 2026. This early-stage preclinical news provides a minor catalyst but no financial impact.
Key Facts
- Pelareorep + RAS inhibitor modalities showed greater anti-tumor activity than individual approaches in a solid tumor model
- Additional studies planned in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models
- Full results from initial preclinical studies expected in fall or winter 2026
- No financial terms or material agreements disclosed
Financial Impact
No financial figures provided; preclinical stage, no immediate revenue or expense impact
Risk Factors
- Preclinical results may not translate to clinical efficacy
- No financial data or guidance provided
- Small-cap biotech volatility with low liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000037 |
| Document: 0001129928-26-000037-index-headers.html | 0001129928-26-000037 |
| Document: 0001129928-26-000037-index.html | 0001129928-26-000037 |
| Document: 0001129928-26-000037.txt | 0001129928-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access